This graphic illustration depicts sugar-coated, mRNA-carrying lipid nanoparticles crossing the blood-brain barrier to treat glioblastoma, the most aggressive form of brain cancer.
Image Credit: Parinaz Ghanbari
Scientific Frontline: Extended "At a Glance" Summary: Targeted Nanoparticle Therapy for Glioblastoma
The Core Concept: Researchers have developed a novel therapeutic approach utilizing sugar-coated lipid nanoparticles to deliver tumor-suppressing genetic material across the blood-brain barrier directly to glioblastoma cells.
Key Distinction/Mechanism: Unlike traditional treatments that struggle to penetrate the brain, these nanoparticles are coated with mannose—a sugar recognized by the brain’s GLUT1 glucose transporters. Because glioblastoma cells overexpress GLUT1 at three times the normal rate, the particles preferentially accumulate in the tumor tissue, where they release messenger RNA to restore the tumor-suppressing protein PTEN.
Major Frameworks/Components:
- Mannose-Coated Lipid Nanoparticles: Delivery vehicles densely coated with sugar chemically linked to cholesterol, allowing them to outcompete blood glucose for transporter binding.
- GLUT1 Transporters: Proteins lining the brain's endothelial cells that shuttle glucose, and the mannose-coated nanoparticles, into the central nervous system.
- PTEN Messenger RNA: Genetic cargo that instructs cells to produce PTEN, a critical tumor-suppressing protein frequently lost in glioblastoma.
- Cationic Cholesterol Derivative: A structural additive utilized to safeguard the mRNA from disruption during systemic delivery.
Branch of Science: Pharmacology, Oncology, Molecular Biology, and Neuroscience.
Future Application: This methodology provides a foundation for highly targeted, non-toxic clinical treatments for human glioblastoma, having already demonstrated a 50% median increase in survival time in a mouse model.
Why It Matters: The innovation successfully bypasses the two most persistent barriers in brain cancer treatment: breaching the blood-brain barrier and achieving selective tumor targeting without causing measurable organ toxicity.
Researchers at Oregon State University have potentially found a new way to treat the most aggressive form of brain cancer, glioblastoma, whose two-year survival rate is less than 30%.
The study, led by Oleh Taratula, Olena Taratula, and Yoon Tae Goo of the OSU College of Pharmacy, addresses what they describe as the two most persistent obstacles to effective glioblastoma treatment: delivering therapeutic agents through the blood-brain barrier, the cell network that acts as a security checkpoint between the bloodstream and the central nervous system, and then getting those agents to preferentially target tumors.
In research published in the Journal of Controlled Release, the scientists demonstrated the novel treatment technique in a mouse model. They loaded lipid nanoparticles with genetic material that promotes tumor suppression, then coated the nanoparticles with a type of sugar. The result was a 50% median increase in glioblastoma survival time.
The sugar they used was mannose, a close relative of glucose, the body’s primary source of energy. The brain’s endothelial cells are lined with a transporter, GLUT1, tasked with shuttling glucose into the central nervous system. However, the transporter recognizes mannose as well, and that is what gets the nanoparticles through the blood-brain barrier.
“Blood contains relatively high concentrations of glucose, and that’s what the nanoparticles are competing against for GLUT1’s attention,” Oleh Taratula said. “For the nanoparticles to get it, they need a densely coated sugar surface, and that’s our central innovation. By chemically connecting mannose to cholesterol, a major structural component of the nanoparticles, we improved surface coverage sixfold.”
Inside the nanoparticles is messenger RNA that enables the production of PTEN, a tumor-thwarting protein that is frequently lost in glioblastoma. To prevent the cargo from being disrupted, the scientists added a cationic cholesterol derivative that safeguards the mRNA encapsulation.
“Glioblastoma is metabolically reprogrammed and expresses GLUT1 at three times the levels of normal brain tissue, so the particles preferentially accumulate in tumor tissue after crossing the blood-brain barrier,” Olena Taratula said. “And restoring PTEN expression in tumor cells reinstates growth control. Across repeated dosing, tumor shrinkage occurred without any measurable organ toxicity.”
In the United States, glioblastoma has an incidence rate of 3.19 per 100,000 people. It is more common in males than females, and the median age of onset is 64; more than 95% of patients live less than five years from the time of diagnosis.
Funding: National Cancer Institute of the National Institutes of Health, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Research Foundation of Korea.
Published in journal: Journal of Controlled Release
Authors: Yoon Tae Goo, Vincent N. Cataldi, Vladislav Grigoriev, Neera Yadav, Tetiana Korzun, Chao Wang, Adam W.G. Alani, Olena R. Taratula, and Oleh Taratula
Source/Credit: Oregon State University | Steve Lundeberg
Edited by: Scientific Frontline
Reference Number: pharm062426_01
.jpg)